Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Palynziq pegvaliase Phenylketonuria Reimburse with clinical criteria and/or conditions Complete
Vraylar cariprazine Bipolar Disorder Do not reimburse Complete
Xydalba dalbavancin Acute bacterial skin and skin structure infections Reimburse with clinical criteria and/or conditions Complete
Tezspire tezepelumab Asthma Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Severe chronic rhinosinusitis with nasal polyps Reimburse with clinical criteria and/or conditions Complete
Tremfya guselkumab Psoriatic arthritis Reimburse with clinical criteria and/or conditions Complete
Zeposia ozanimod Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab recurrent, or metastatic cervical cancer Reimburse with clinical criteria and/or conditions Complete
Wakix pitolisant hydrochloride Narcolepsy Do not reimburse Complete
Ozurdex dexamethasone intravitreal implant Diabetic macular edema Do not reimburse Complete